Cardiac Risk Articles & Analysis
10 news found
” The product labels of all JAK inhibitors will be updated to include a precautionary approach for patients aged 65 years or above, those at increased risk of major cardiovascular problems (such as heart attack or stroke), those who smoke or have done so for a long time in the past and those at increased risk of cancer. ...
(NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced a significant milestone of recording and analyzing over 2 billion heartbeats for Atrial Fibrillation (AFib), the most common type of cardiac arrhythmia and a leading cause of stroke. Bioflux®, Biotricity’s ...
The research shows that the two-week, artificial intelligence-powered Zio system doesn’t just aid in diagnosing afib in patients with a standard risk level, but also helps monitor higher-risk patients after cardiac and other procedures, potentially saving hospitals time, money and bed space. ...
The procedure was performed by cardiac electrophysiologist James D. Allred. M.D. and vascular surgeon Wells Brabham, M.D.. at The Moses H. ...
ByCVRx
Its Makoto Intravascular Imaging System, with accompanying Dualpro IVUS+NIRS catheter, is the only technology on the market that is FDA-cleared for the detection of lipid core plaque (LCP) and the identification of patients and plaques at increased risk of major adverse cardiac events (MACE). Infraredx is a wholly owned subsidiary of the Nipro ...
A summary of the abstracts are as follows: The REMOVE (“Revealing Mechanisms and Investigating Efficiency Of Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients with Infective Endocarditis“) investigator initiated randomized, controlled trial enrolled 288 patients with documented infective endocarditis with a EuroSCORE II (European System ...
South Korean artificial intelligence (AI) developer, VUNO Inc. announced today that it has received regulatory approval from the Ministry of Food and Drug Safety (MFDS) for its VUNO Med®–DeepCARS™, an AI medical device for cardiac arrest prediction through vital signs. VUNO Med®–DeepCARS™ is a breakthrough AI-driven medical device that analyzes ...
For example, research has suggested that the presence of low attenuation plaque that shows up via CTA indicates that the patient is at risk of having a heart attack. “What our technology does, and what we are pleased to be working on, is a way to make that more specific to be able to discriminate tissues that have histopathologic correlates, and the importance of that is ...
ByElucid
Lungpacer Medical, Inc., a medical device company developing an intravenous catheter-based phrenic-nerve-pacing system, announced today that the FDA has approved the Emergency Use Authorization for the use of the Lungpacer Diaphragm Pacing Therapy System (DPTS) to assist in weaning patients determined by their healthcare provider to be at high risk of weaning failure. According ...
The approval is based on the results of the landmark Lipid-Rich Plaque (LRP) Study, which demonstrated the ability of intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) technology to identify patients and coronary plaques at an increased risk for major adverse cardiac events (MACE). The study, which enrolled 1,563 patients from 44 sites across ...